HIV-1 eradication strategies: Design and assessment

Current Opinion in HIV and AIDS

Volumn 8, Issue 4, 2013, Pages 318-325

  Siliciano, Janet D ^a   Siliciano, Robert F ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

eradication; HIV latency; reservoir

Indexed keywords

ANTIRETROVIRUS AGENT; DISULFIRAM; HISTONE DEACETYLASE INHIBITOR; LATENCY REVERSING AGENT; UNCLASSIFIED DRUG; VORINOSTAT;

CD4+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DYNAMICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RESERVOIR; REVIEW; T LYMPHOCYTE ACTIVATION; VIRAL CLEARANCE; VIREMIA; VIRUS LATENCY; VIRUS REPLICATION;

CD4-POSITIVE T-LYMPHOCYTES; DISEASE ERADICATION; HIV INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; VIRUS LATENCY;

EID: 84880330155     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328361eaca     Document Type: Review

References (57)

1. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360:692-698.
2. Richman DD, Margolis DM, Delaney M, et al. The challenge of finding a cure for HIV infection. Science 2009; 323:1304-1307.
3. Deeks SG, Autran B, Berkhout B, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012; 12:607-614.
4. Chun TW, Finzi D, Margolick J, et al. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1995; 1:1284-1290.
5. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387:183-188.
6. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-1300.
7. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278: 1291-1295.
8. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997; 94:13193-13197.
9. \+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-517.
10. \+ T cells. Nat Med 2003; 9:727-728.
11. Strain MC, Gunthard HF, Havlir DV, et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci USA 2003; 100:4819-4824.
12. WeiX, Ghosh SK, Taylor ME, et al. Viral dynamicsinhuman immunodeficiency virus type 1 infection. Nature 1995; 373:117-122.
13. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-126.
14. Nowak MA, Lloyd AL, Vasquez GM, et al. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol 1997; 71:7518-7525.
15. Wodarz D, Nowak MA. Mathematical models of HIV pathogenesis and treatment. Bioessays 2002; 24:1178-1187.
16. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271:1582-1586.
17. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:188-191.
18. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-733.
19. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-739.
20. Berger A, Sommer AF, Zwarg J, et al. SAMHD1-deficient CD14\+ cells from individuals with Aicardi-Goutieres syndrome are highly susceptible to HIV-1 infection. PLoS Pathog 2011; 7:e1002425.
21. Laguette N, Sobhian B, Casartelli N, et al. SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011; 474:654-657.
22. Siekevitz M, Josephs SF, Dukovich M, et al. Activation of the HIV-1 LTR by T cell mitogens and the trans-activator protein of HTLV-I. Science 1987; 238:1575-1578.
23. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 1987; 326:711-713.
24. Bohnlein E, Lowenthal JW, Siekevitz M, et al. The same inducible nuclear proteins regulates mitogen activation of both the interleukin-2 receptor-alpha gene and type 1 HIV. Cell 1988; 53:827-836.
25. Duh EJ, Maury WJ, Folks TM, et al. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci USA 1989; 86:5974-5978.
26. \+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol 2005; 304:3-15.
27. Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcrip-tase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41:4531-4536.
28. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2008; 105:3879-3884.
29. \+ T cells. J Virol 2006; 80:6441-6457.
30. Davey RT Jr, Bhat N, Yoder C, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999; 96:15109-15114.
31. Kulkosky J, Nunnari G, Otero M, et al. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J Infect Dis 2002; 186:1403-1411.
32. Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 2003; 22:1868-1877.
33. Yang HC. Primary cell models of HIV latency. Curr Opin HIV AIDS 2011; 6:62-67.
34. Williams SA, Greene WC. Regulation of HIV-1 latency by T-cell activation. Cytokine 2007; 39:63-74.
35. Siliciano RF, Greene WC. HIV latency. Cold Spring Harb Perspect Med 2011; 1:a007096.
36. Karn J. The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit. Curr Opin HIV AIDS 2011; 6:4-11.
37. Ylisastigui L, Archin NM, Lehrman G, et al. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004; 18:1101-1108.
38. Archin NM, Espeseth A, Parker D, et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 2009; 25:207-212.
39. Contreras X, Schweneker M, Chen CS, et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 2009; 284:6782-6789.
40. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487:482-485.
41. Yang HC, Xing S, Shan L, et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 2009; 119:3473-3486.
42. \+ T cell model without inducing global T cell activation. J Virol 2011; 85:6060-6064.
43. \+ T cell model without inducing global T cell activation. J Antimicrob Chemother 2012; 67:398-403.
44. Blazkova J, Chun TW, Belay BW, et al. Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(\+) T cells from infected individuals receiving effective antiretroviral therapy. J Infect Dis 2012; 206:765-769.
45. Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012; 36:491-501.
46. Eriksson S, Graf EH, Dahl V, et al. Comparative analysis of measures of viral && reservoirs in HIV-1 eradication studies. PLoS Pathog 2013; 9:e1003174.
47. Strain MC, Richman DD. New assays for monitoring residual HIV & burden in effectively treated individuals. Curr Opin HIV AIDS 2013; 8: 106-110.
48. O'Doherty U, Swiggard WJ, Jeyakumar D, et al. A sensitive, quantitative assay for human immunodeficiency virus type 1 integration. J Virol 2002; 76:10942-10950.
49. Graf EH, Mexas AM, Yu JJ, et al. Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV\+ patients on and off HAART. PLoS Pathog 2011; 7:e1001300.
50. Bukrinsky MI, Stanwick TL, Dempsey MP, Stevenson M. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 1991; 254:423-427.
51. Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999; 282:1627-1632.
52. Maldarelli F, Palmer S, King MS, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007; 3:e46.
53. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418:646-650.
54. Harris RS, Bishop KN, Sheehy AM, et al. DNA deamination mediates innate immunity to retroviral infection. Cell 2003; 113:803-809.
55. Malim MH, Emerman M. HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe 2008; 3:388-398.
56. \+ T cells in vivo. J Virol 2005; 79:1975-1980.
57. Sanchez G, Xu X, Chermann JC, Hirsch I. Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals. J Virol 1997; 71:2233-2240.